160 related articles for article (PubMed ID: 21517810)
1. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
Di Martino MT; Arbitrio M; Guzzi PH; Leone E; Baudi F; Piro E; Prantera T; Cucinotto I; Calimeri T; Rossi M; Veltri P; Cannataro M; Tagliaferri P; Tassone P
Br J Haematol; 2011 Aug; 154(4):529-33. PubMed ID: 21517810
[No Abstract] [Full Text] [Related]
2. [Avascular osteonecrosis of the jaws induced by diphosphonates].
Lannoy D; Decaudin B; Barrier F; Bemba M; Wierre L; Pignon JM; Horrent S; Résibois JP; Wetterwald M; Odou P
Therapie; 2006; 61(4):363-5. PubMed ID: 17124954
[No Abstract] [Full Text] [Related]
3. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'Arco A; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S; Baccarani M; Cavo M
Blood; 2006 Dec; 108(12):3951-2. PubMed ID: 17114572
[No Abstract] [Full Text] [Related]
4. [Osteonecrosis associated with the use of biphosphonates: Case report].
Anguita C T; Agurto P J; Roa E I; Laissle C G
Rev Med Chil; 2006 Sep; 134(9):1161-5. PubMed ID: 17171218
[TBL] [Abstract][Full Text] [Related]
5. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
Arduino PG; Menegatti E; Scoletta M; Battaglio C; Mozzati M; Chiecchio A; Berardi D; Vandone AM; Donadio M; Gandolfo S; Scully C; Broccoletti R
J Oral Pathol Med; 2011 Jul; 40(6):510-5. PubMed ID: 21251073
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Katz J; Gong Y; Salmasinia D; Hou W; Burkley B; Ferreira P; Casanova O; Langaee TY; Moreb JS
Int J Oral Maxillofac Surg; 2011 Jun; 40(6):605-11. PubMed ID: 21396799
[TBL] [Abstract][Full Text] [Related]
8. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.
Kastritis E; Melea P; Bagratuni T; Melakopoulos I; Gavriatopoulou M; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Oct; 58(10):2304-2309. PubMed ID: 28604257
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw.
Sari E; Bulut N; Altundag K
J Am Dent Assoc; 2008 Apr; 139(4):398; author reply 398-400. PubMed ID: 18385020
[No Abstract] [Full Text] [Related]
10. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
11. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Dimopoulos MA; Kastritis E; Bamia C; Melakopoulos I; Gika D; Roussou M; Migkou M; Eleftherakis-Papaiakovou E; Christoulas D; Terpos E; Bamias A
Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
Gibbs SD; O'Grady J; Seymour JF; Prince HM
Med J Aust; 2005 Nov; 183(10):549-50. PubMed ID: 16296983
[No Abstract] [Full Text] [Related]
13. More about osteonecrosis.
Finkelman RD; Clemons M; Bouganim N
J Am Dent Assoc; 2011 Apr; 142(4):371-2; author reply 372-4. PubMed ID: 21454842
[No Abstract] [Full Text] [Related]
14. [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Neumann B; Gregersen H
Ugeskr Laeger; 2006 May; 168(21):2078-9. PubMed ID: 16768928
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates inhibit expression of p63 by oral keratinocytes.
Scheller EL; Baldwin CM; Kuo S; D'Silva NJ; Feinberg SE; Krebsbach PH; Edwards PC
J Dent Res; 2011 Jul; 90(7):894-9. PubMed ID: 21551338
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Olson KB; Hellie CM; Pienta KJ
Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
[No Abstract] [Full Text] [Related]
19. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
20. [Jaw fistulas in 75 years-old woman].
Estellés RA; López CC; Jiménez JA; Agulló FD
Rev Clin Esp; 2008 Mar; 208(3):165-7. PubMed ID: 18275774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
